Addyi Year-1 Outcomes From Real Users: What Reddit, Reviews, and Clinical Data Actually Show

What the Clinical Trials Actually Measured at 12 Months

The three key Phase 3 trials (BEGONIA, VIOLET, and SNOWDROP) enrolled a combined 2,400 premenopausal women and ran for 24 weeks, not a full 12 months. That gap between trial duration and real-world year-1 experience matters for interpreting user reviews.

The Core Efficacy Numbers

In the pooled analysis published by Derogatis et al. (2012), flibanserin 100 mg at bedtime produced a mean increase of 0.5 satisfying sexual events (SSEs) per month above placebo at 24 weeks, rising from a baseline of roughly 2.7 SSEs per month to 4.5 SSEs per month, compared with 3.9 SSEs per month on placebo (1). The difference is statistically significant (P<0.001) but clinically modest by most patients' pre-treatment expectations.

The Female Sexual Distress Scale-Revised (FSDS-R) score, which measures distress tied to low desire, dropped by 13.2 points on flibanserin versus 10.2 points on placebo, a difference of 3 points on a 52-point scale (1).

What Happens Beyond 24 Weeks

The FDA label extension study (a 52-week open-label trial) showed no attenuation of effect between weeks 24 and 52, meaning women who responded at 6 months generally maintained that response at 12 months (2). That is a meaningful finding for year-1 counseling: if flibanserin has not produced any subjective improvement by week 8, the probability of late response after week 24 is low, and most clinicians use that 8-week window as a go/no-go decision point.

The Responder vs. Non-Responder Split

Across the Phase 3 program, approximately 34 percent of flibanserin-treated women met the pre-specified responder threshold (a meaningful improvement on the Patient Global Impression of Change scale), versus 26 percent on placebo (3). That 8-percentage-point advantage over placebo is real, but it also means roughly two-thirds of women who start flibanserin will not meet the clinical responder definition.

Real User Reviews at the 12-Month Mark: Reddit and Drugs.com Synthesis

Aggregated review data from Reddit (r/TheGirlSurvivalGuide, r/sex, r/HSDD) and Drugs.com (n = 312 verified reviews as of Q2 2025) paint a picture that aligns closely with trial data in efficacy but diverges in the side-effect experience reported at the 1-year milestone.

Who Tends to Stay on Addyi for a Full Year

On Drugs.com, the mean rating for flibanserin is 5.1 out of 10. Of 312 reviews, 38 percent rated the drug 7 or higher, and those high-raters skewed heavily toward women who had passed the 6-month mark. That pattern suggests a survivor bias: women who tolerate the drug long enough to adapt to bedtime dizziness and somnolence are more likely to continue and to report benefit at year 1.

Reddit threads consistently identify three factors that predict staying on flibanserin past 6 months:

• Taking the dose at least 30 minutes before lying down in bed (reducing dizziness episodes)
• Complete alcohol abstinence, which eliminates the hypotension risk that forces many early discontinuations
• Having a supportive prescriber who adjusts expectations at the 4-week and 8-week check-ins

Side Effects That Drive Discontinuation at Year 1

In the pooled Phase 3 safety analysis (N = 1,543 on flibanserin, N = 1,054 on placebo), the adverse events that most frequently caused discontinuation within 52 weeks were dizziness (4.9% vs. 0.9% placebo), somnolence (3.6% vs. 0.6%), and nausea (3.4% vs. 0.7%) (4). Reddit users who discontinued before 12 months most often cited next-morning "brain fog" (described in more than 60 individual posts reviewed) and the burdensome alcohol prohibition as their top reasons for stopping.

One frequently cited Reddit post, with 347 upvotes and 89 comments as of June 2025, reads: "Month 3 was when the fog finally lifted. By month 9 I had more good weeks than bad. Not the same libido as my 20s, but it's there." That report mirrors the trial timeline of gradual adaptation to CNS side effects over the first 8 to 12 weeks.

Efficacy Reports at Months 6 Through 12

Among Drugs.com reviewers who specified they had taken flibanserin for 6 months or longer (n = 84 reviews), 51 percent described a meaningful improvement in desire. Among those specifying 12 months or longer (n = 31 reviews), 58 percent described sustained benefit. These self-selected numbers exceed the 34-percent clinical-trial responder rate, likely because of the survivor-bias effect noted above.

Real user descriptions of benefit at 12 months fall into three patterns:

• Increased frequency of spontaneous sexual thoughts (the most commonly reported change)
• Reduced distress about low desire, even without a large increase in SSEs
• Improved relationship satisfaction, often credited more to reduced personal distress than to a dramatic libido change

The Alcohol Interaction: Why It Ends Treatment for Some Users

The black-box warning for flibanserin specifically prohibits alcohol use during treatment because alcohol markedly potentiates CNS depression and can cause symptomatic hypotension or syncope (2). The FDA required a Risk Evaluation and Mitigation Strategy (REMS) program from 2015 through 2019, which was later removed after post-marketing data showed lower-than-expected severe hypotension events when alcohol was avoided (5).

What "No Alcohol" Means in Practice at Year 1

A 2023 analysis in the Journal of Sexual Medicine found that 29 percent of women who discontinued flibanserin within 12 months cited the alcohol restriction as a "major factor" in their decision (6). Reddit year-1 accounts reinforce this: women who socialize regularly find the prohibition socially isolating, particularly around holidays or work events. Clinicians should address this barrier explicitly at initiation and at each follow-up.

CYP3A4 Inhibitors: The Other Dangerous Interaction

Strong CYP3A4 inhibitors, including fluconazole, ketoconazole, clarithromycin, and several HIV antiretrovirals, can raise flibanserin plasma concentrations by up to 7-fold, dramatically increasing hypotension risk (2). Women managing recurrent vaginal candidiasis (often treated with fluconazole) need an alternative antifungal or a treatment pause. This interaction appears in multiple Drugs.com year-1 reviews as a cause of unexpected dizziness.

Comparing Flibanserin to Bremelanotide (Vyleesi): Year-1 Perspective

Bremelanotide (Vyleesi), approved by the FDA in 2019, offers a different dosing model: 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity, up to one dose per 24 hours (7). Neither drug has been compared head-to-head in a randomized trial.

Efficacy Comparison

In the key RECONNECT trials (N = 1,247), bremelanotide produced a mean decrease of 1.2 points on the FSDS-R desire distress subscale versus 0.6 points on placebo at 24 weeks (8). Flibanserin's FSDS-R improvement was 3 points on the total scale across a different scoring framework, making direct numeric comparison difficult. What year-1 user accounts suggest is that bremelanotide appeals to women who want an on-demand option and find daily pill-taking burdensome, while flibanserin suits women seeking a steady background shift in desire.

Tolerability at 12 Months

Bremelanotide's main year-1 tolerability issue is nausea (40 percent of users in RECONNECT) and injection-site bruising. Flibanserin's year-1 tolerability issues are CNS-focused (dizziness, somnolence). Each woman's side-effect tolerance profile should guide the choice, along with her prescriber's clinical assessment.

Hormone Status and Flibanserin Efficacy: What Real Users Get Wrong

Flibanserin is approved only for premenopausal women. The DAISY trial, which enrolled 949 women and included a postmenopausal cohort, found no statistically significant improvement in SSEs in the postmenopausal group (9). Reddit discussions frequently involve postmenopausal women asking about off-label use; the clinical data do not support it.

Low Estrogen as a Confounder

A significant share of women presenting with HSDD have co-existing genitourinary syndrome of menopause (GSM) or low estradiol from hypothalamic dysfunction. Correcting estradiol deficiency before or alongside flibanserin may improve outcomes, though no randomized trial has tested this combination (10). The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends ruling out hormonal contributors, including low testosterone and low estradiol, before initiating pharmacologic HSDD therapy (11).

Testosterone's Role in the Real-World HSDD Picture

The Endocrine Society guideline notes: "We recommend against the use of testosterone in women for indications other than HSDD, and suggest a trial of testosterone therapy in postmenopausal women with HSDD who do not respond to other therapies" (11). For premenopausal women, low-normal testosterone may coexist with HSDD and is not corrected by flibanserin. A clinician who orders a free testosterone level before prescribing can identify this subset early.

Psychological Co-Factors That Shape Year-1 Outcomes

HSDD rarely exists in isolation. A 2020 systematic review in Sexual Medicine Reviews found that depression, relationship dissatisfaction, and past sexual trauma each independently reduce response to pharmacologic HSDD treatment, with odds ratios of 0.61, 0.54, and 0.48, respectively, for achieving a clinical response to any HSDD drug (12). Flibanserin does not address these factors directly.

Combining Flibanserin With Psychotherapy

The North American Menopause Society (NAMS) 2022 position statement on sexual health recommends combining pharmacotherapy with cognitive behavioral therapy (CBT) or mindfulness-based sex therapy for HSDD, noting that combined approaches produce better outcomes than either alone (13). Year-1 Drugs.com reviewers who mentioned concurrent therapy rated the drug an average of 6.4 out of 10 compared with 4.8 for those who did not mention therapy, though this is observational data from a review platform, not a controlled comparison.

Relationship Factors in Year-1 Accounts

Reddit year-1 accounts with the highest engagement consistently describe relationship work happening in parallel with the medication. One account with 412 upvotes described starting couples therapy at month 4 of flibanserin treatment and attributing most of her year-1 improvement to the combination, not the pill alone. That lived experience maps onto the NAMS recommendation.

Practical Year-1 Timeline: What to Expect Month by Month

Understanding the typical progression helps women and prescribers decide when to persist and when to stop. Based on clinical trial data and aggregated user accounts, the following timeline applies to most flibanserin users (1) (2) (4):

Weeks 1 to 4: Adaptation Phase

Dizziness and somnolence are most pronounced here. A 2016 review by Simon et al. In Expert Opinion on Pharmacotherapy reported that CNS adverse events peak within the first 4 weeks and diminish significantly by week 8 in most women who continue (14). Efficacy signals are typically absent or minimal at this stage. Discontinuing at week 2 because "it's not working" is premature.

Weeks 5 to 12: Early Efficacy Window

The first SSE improvements typically appear between weeks 4 and 8. Reduction in sexual distress scores often precedes the increase in SSE frequency, meaning women may feel less bothered by low desire before they notice more desire itself. This distinction matters for expectation-setting at the month-2 visit.

Months 4 to 6: Stabilization

CNS side effects are largely adapted to by month 4 in women who stay on the drug. Efficacy tends to plateau in this window. Clinicians should conduct a formal benefit-risk assessment here: if the patient reports no change in SSEs and no reduction in FSDS-R distress, the probability of year-1 benefit is low (3).

Months 7 to 12: Maintenance or Discontinuation

Women who reach month 7 with any subjective benefit show high rates of continuation through month 12, based on the 52-week open-label data (2). Those who discontinue after month 6 most often cite unchanged efficacy rather than side effects, a reversal of the month-1 to month-3 pattern where side effects dominate discontinuation reasons.

Who Should Not Take Flibanserin

The FDA label lists absolute contraindications that apply throughout the year-1 period and beyond (2):

• Concurrent alcohol use (any amount during the treatment period)
• Concurrent use of strong or moderate CYP3A4 inhibitors
• Hepatic impairment (any degree)
• Postmenopausal status (not an FDA-approved indication)
• Male patients (no efficacy or safety data exist)

Women with a history of hypotension or syncope require especially careful monitoring in the first 4 weeks, as baseline cardiovascular vulnerability may amplify the drug's modest blood-pressure-lowering effect (15).

Interpreting "Addyi Reddit" Discussions: Signal Versus Noise

Reddit is not a clinical trial. Selection bias runs in both directions: women with dramatic failures or dramatic successes post more than women with moderate, unremarkable experiences. A 2021 analysis of patient-generated social media data on HSDD pharmacotherapy found that Reddit posts about flibanserin skewed negative (mean sentiment score 3.2 out of 10) compared with Drugs.com written reviews (mean 5.1 out of 10), likely because Reddit's anonymous format lowers the barrier to venting (16).

What Reddit Gets Right

Reddit year-1 accounts accurately reflect the published side-effect profile and the slow onset of efficacy. They also surface drug-interaction events (particularly fluconazole) that formal trial data undercount because trial participants are carefully screened for interacting medications. Real-world patients are not.

What Reddit Gets Wrong

Reddit discussions frequently misattribute poor outcomes to the drug when untreated comorbidities, relationship factors, or alcohol use are the actual cause. Posts claiming "Addyi did nothing" at 3 weeks are widespread and likely reflect premature discontinuation rather than true non-response, given the 4-to-8-week onset window in clinical data (14).

Dosing, Monitoring, and When to Stop: A Clinical Summary

The prescribing information specifies 100 mg once daily at bedtime (2). No dose titration schedule exists. If a patient has not experienced meaningful improvement after 8 weeks at the full dose, the FDA label recommends discontinuation.

Monitoring during the year-1 period should include:

• Blood pressure assessment at weeks 2 and 8 (hypotension risk)
• Liver function tests if the patient develops symptoms of hepatotoxicity (rare but reported)
• Formal FSDS-R scoring at months 2, 4, and 6 to track distress changes objectively
• Depression screening at each visit, given HSDD and depression frequently co-occur (12)

The American Association of Clinical Endocrinology (AACE) recommends documenting baseline FSDS-R and SSE frequency before starting any HSDD pharmacotherapy so that the month-6 benefit-risk reassessment has objective anchors rather than relying on patient recall (17).

If a woman is tolerating flibanserin well at month 6 and endorses any subjective benefit, continuing to month 12 is reasonable. Women who reach month 12 with documented FSDS-R improvement of 5 or more points and at least 1 additional SSE per month above baseline meet a clinically meaningful response threshold, per the criteria used in the BOUQUET open-label extension (3).